Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)

NCT05953688 is registered in ClinicalTrials.gov with Alumis Inc as lead sponsor.

NCT NCT05953688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05953688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept, Randomized, Double-Masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Noninfectious Intermediate, Posterior, or Panuveitis (OPTYK-1)
Lead sponsor
Alumis Inc
Phase
Phase 2
Overall status
Terminated
Start date
June 14, 2023
Completion date
August 13, 2024
Enrollment
36 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

noninfectious panuveitis, uveitis posterior non-infectious, uveitis, intermediate